FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2304217417> ?p ?o ?g. }

• W2304217417 endingPage "1678" @default.
• W2304217417 startingPage "1668" @default.
• W2304217417 abstract "A promising strategy to enable patient stratification for targeted therapies is to monitor the target expression in a tumor by radionuclide molecular imaging. Affibody molecules (7 kDa) are nonimmunoglobulin scaffold proteins with a 25-fold smaller size than intact antibodies. They have shown an apparent potential as molecular imaging probes both in preclinical and clinical studies. Earlier, we found that hepatic uptake can be reduced by the incorporation of negatively charged purification tags at the N-terminus of Affibody molecules. We hypothesized that liver uptake might similarly be reduced by positioning the chelator at the N-terminus, where the chelator-radionuclide complex will provide negative charges. To test this hypothesis, a second generation synthetic anti-HER2 ZHER2:2891 Affibody molecule was synthesized and labeled with (111)In and (68)Ga using DOTAGA and DOTA chelators. The chelators were manually coupled to the N-terminus of ZHER2:2891 forming an amide bond. Labeling DOTAGA-ZHER2:2891 and DOTA-ZHER2:2891 with (68)Ga and (111)In resulted in stable radioconjugates. The tumor-targeting and biodistribution properties of the (111)In- and (68)Ga-labeled conjugates were compared in SKOV-3 tumor-bearing nude mice at 2 h postinjection. The HER2-specific binding of the radioconjugates was verified both in vitro and in vivo. Using the DOTAGA chelator gave significantly lower radioactivity in liver and blood for both radionuclides. The (111)In-labeled conjugates showed more rapid blood clearance than the (68)Ga-labeled conjugates. The most pronounced influence of the chelators was found when they were labeled with (68)Ga. The DOTAGA chelator gave significantly higher tumor-to-blood (61 ± 6 vs 23 ± 5, p < 0.05) and tumor-to-liver (10.4 ± 0.6 vs 4.5 ± 0.5, p < 0.05) ratios than the DOTA chelator. This study demonstrated that chelators may be used to alter the uptake of Affibody molecules, and most likely other scaffold-based imaging probes, for improvement of imaging contrast." @default.
• W2304217417 created "2016-06-24" @default.
• W2304217417 creator A5014071440 @default.
• W2304217417 creator A5032332213 @default.
• W2304217417 creator A5037938392 @default.
• W2304217417 creator A5046621958 @default.
• W2304217417 creator A5051105199 @default.
• W2304217417 creator A5053008755 @default.
• W2304217417 creator A5074441028 @default.
• W2304217417 creator A5090698986 @default.
• W2304217417 date "2016-04-06" @default.
• W2304217417 modified "2023-10-17" @default.
• W2304217417 title "Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules" @default.
• W2304217417 cites W165471803 @default.
• W2304217417 cites W1926190291 @default.
• W2304217417 cites W1946074662 @default.
• W2304217417 cites W1965040263 @default.
• W2304217417 cites W1965706807 @default.
• W2304217417 cites W1966335626 @default.
• W2304217417 cites W1973910939 @default.
• W2304217417 cites W1977451764 @default.
• W2304217417 cites W1978612656 @default.
• W2304217417 cites W1983031498 @default.
• W2304217417 cites W1991946507 @default.
• W2304217417 cites W1994040531 @default.
• W2304217417 cites W1995823770 @default.
• W2304217417 cites W1996032015 @default.
• W2304217417 cites W1997987445 @default.
• W2304217417 cites W1998315961 @default.
• W2304217417 cites W1999587638 @default.
• W2304217417 cites W2000269004 @default.
• W2304217417 cites W2001408389 @default.
• W2304217417 cites W2001784729 @default.
• W2304217417 cites W2008883059 @default.
• W2304217417 cites W2009587915 @default.
• W2304217417 cites W2012966854 @default.
• W2304217417 cites W2016016353 @default.
• W2304217417 cites W2017170622 @default.
• W2304217417 cites W2030008772 @default.
• W2304217417 cites W2031606304 @default.
• W2304217417 cites W2036752075 @default.
• W2304217417 cites W2046953922 @default.
• W2304217417 cites W2049089156 @default.
• W2304217417 cites W2049109062 @default.
• W2304217417 cites W2055144800 @default.
• W2304217417 cites W2055421103 @default.
• W2304217417 cites W2059715782 @default.
• W2304217417 cites W2060740491 @default.
• W2304217417 cites W2063823414 @default.
• W2304217417 cites W2076664198 @default.
• W2304217417 cites W2076948240 @default.
• W2304217417 cites W2077787026 @default.
• W2304217417 cites W2079688396 @default.
• W2304217417 cites W2092072407 @default.
• W2304217417 cites W2100439220 @default.
• W2304217417 cites W2118167053 @default.
• W2304217417 cites W2126661996 @default.
• W2304217417 cites W2127797287 @default.
• W2304217417 cites W2128941143 @default.
• W2304217417 cites W2132154075 @default.
• W2304217417 cites W2132840811 @default.
• W2304217417 cites W2155847415 @default.
• W2304217417 cites W2160125502 @default.
• W2304217417 cites W2163390231 @default.
• W2304217417 cites W2167669893 @default.
• W2304217417 cites W2170132049 @default.
• W2304217417 cites W2171070913 @default.
• W2304217417 cites W2285875128 @default.
• W2304217417 doi "https://doi.org/10.1021/acs.molpharmaceut.6b00089" @default.
• W2304217417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27010700" @default.
• W2304217417 hasPublicationYear "2016" @default.
• W2304217417 type Work @default.
• W2304217417 sameAs 2304217417 @default.
• W2304217417 citedByCount "34" @default.
• W2304217417 countsByYear W23042174172016 @default.
• W2304217417 countsByYear W23042174172017 @default.
• W2304217417 countsByYear W23042174172018 @default.
• W2304217417 countsByYear W23042174172019 @default.
• W2304217417 countsByYear W23042174172020 @default.
• W2304217417 countsByYear W23042174172021 @default.
• W2304217417 countsByYear W23042174172022 @default.
• W2304217417 countsByYear W23042174172023 @default.
• W2304217417 crossrefType "journal-article" @default.
• W2304217417 hasAuthorship W2304217417A5014071440 @default.
• W2304217417 hasAuthorship W2304217417A5032332213 @default.
• W2304217417 hasAuthorship W2304217417A5037938392 @default.
• W2304217417 hasAuthorship W2304217417A5046621958 @default.
• W2304217417 hasAuthorship W2304217417A5051105199 @default.
• W2304217417 hasAuthorship W2304217417A5053008755 @default.
• W2304217417 hasAuthorship W2304217417A5074441028 @default.
• W2304217417 hasAuthorship W2304217417A5090698986 @default.
• W2304217417 hasConcept C12554922 @default.
• W2304217417 hasConcept C134306372 @default.
• W2304217417 hasConcept C150903083 @default.
• W2304217417 hasConcept C161624437 @default.
• W2304217417 hasConcept C178790620 @default.
• W2304217417 hasConcept C185592680 @default.
• W2304217417 hasConcept C197336794 @default.

• next